Centella asiatica / Gotu kola → asiaticoside / LDH Cancer Research Results

Cen, Centella asiatica / Gotu kola → asiaticoside: Click to Expand ⟱
Features:

Centella asiatica / Gotu kola → Asiaticoside

Centella asiatica, commonly known as Gotu kola, is a medicinal botanical used mainly for wound healing, skin repair, microcirculation support, anti-inflammatory effects, and possible neuroprotective activity.

  • Primary database product: Centella asiatica standardized extract
  • Common name / alias: Gotu kola
  • Other aliases: Indian pennywort, tiger grass, cica
  • Best form: Standardized Centella asiatica extract / titrated triterpenes
  • Main active marker: Asiaticoside
  • Other key actives: Madecassoside, asiatic acid, madecassic acid
  • Compound class: Pentacyclic triterpenoid saponins / triterpenes

Asiaticoside is one of the major active and marker compounds in Centella asiatica.

  • Asiaticoside role: Active constituent / quality marker
  • Source: Centella asiatica / Gotu kola
  • Main activities: Wound repair, collagen synthesis, fibroblast support, anti-inflammatory, antioxidant, skin barrier support
  • Relevant pathways: TGF-β/collagen, VEGF/angiogenesis, NF-κB, IL-1β, IL-6, TNF-α, COX-2/PGE2, oxidative stress pathways

Structure: 

Centella asiatica / Gotu kola
  → Asiaticoside
  → Madecassoside
  → Asiatic acid
  → Madecassic acid

Centella asiatica / Gotu kola → asiaticoside — Centella asiatica is a medicinal botanical extract source, and asiaticoside is one of its major pentacyclic triterpenoid saponin marker constituents. The formal classification is botanical standardized extract / natural-product triterpenoid saponin modality, not an approved anticancer drug. The principal active family includes asiaticoside, madecassoside, asiatic acid, and madecassic acid; asiaticoside can also be metabolically linked to asiatic acid. Asiaticoside as the main active marker, with Centella asiatica standardized extract as the primary product.

Primary mechanisms (ranked):

  1. NF-κB and inflammatory cytokine suppression, especially reduced TNF-α, IL-1β, IL-6, COX-2/PGE2, and downstream survival signaling in inflammatory and tumor models.
  2. Mitochondrial apoptosis induction in cancer cells, with Bax:Bcl-2 shift, MMP loss, caspase-9 activation, caspase-3 activation, and p53/p21-associated cell-cycle arrest reported in preclinical models.
  3. Anti-migration and anti-EMT effects, including suppression of p65/NF-κB-linked EMT, YAP1/VEGFA signaling, invasion, and radiation-induced migration in selected cancer-cell systems.
  4. PI3K/Akt/mTOR/STAT3 modulation, more strongly supported for asiatic acid than for asiaticoside itself, with relevance to proliferation, survival, autophagy, and metastatic phenotype.
  5. TGF-β/collagen/fibroblast and wound-repair axis activation in normal tissue contexts; beneficial for repair but mechanistically ambiguous in cancer because fibrosis and angiogenesis can be tumor-context dependent.
  6. Oxidative-stress modulation, generally antioxidant and cytoprotective in normal cells; ROS/NRF2 effects are secondary and context-dependent rather than the core anticancer mechanism.

Bioavailability / PK relevance: Oral translation is constrained by variable extract composition, limited dissolution and bioavailability of triterpenes, metabolism of glycosides to aglycones, and formulation dependence. Standardized extracts such as ECa 233 and aqueous Centella asiatica products have human phase-1 PK data, but systemic exposure is still not equivalent to common high-concentration in-vitro cancer experiments.

In-vitro vs systemic exposure relevance: Cancer-cell studies commonly use micromolar asiaticoside or asiatic-acid exposures that may exceed or not cleanly map onto achievable plasma exposure after oral botanical dosing. Topical and local tissue uses are more plausible for skin/wound biology than systemic anticancer effects. For cancer translation, the entry should be treated as concentration- and formulation-dependent.

Clinical evidence status: Cancer relevance is weak / preclinical only, with no established oncology indication. Human evidence is stronger for wound healing, venous/skin-related uses, and early cognitive/AD-oriented safety or PK studies than for cancer treatment. AD relevance is possible / early clinical, with phase-1 target-engagement work in mild cognitive impairment or mild Alzheimer’s disease, but no proven disease-modifying efficacy.

Centella asiatica and Asiaticoside Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB inflammatory survival axis NF-κB↓, p65↓, TNF-α↓, IL-1β↓ NF-κB↓, inflammatory cytokines↓ R,G Anti-inflammatory and anti-survival signaling Most central cross-context mechanism; supports anticancer, neuroinflammatory, and wound-healing interpretations but is not cancer-specific.
2 Mitochondrial apoptosis MMP↓, Bax:Bcl-2↑, caspase-9↑, caspase-3↑ Apoptosis↔ or ↓ in injury models (context-dependent) G Intrinsic apoptotic priming in tumor models Preclinical cancer-cell effect; selectivity depends strongly on dose, cell line, and compound form.
3 Cell-cycle checkpoint and p53 axis p53↑, p21↑, cyclin D1↓, CDK4↓ Cell-cycle stress↔ (context-dependent) G Growth arrest and reduced proliferation cytostatic activity; best treated as model-dependent rather than universal.
4 EMT migration invasion axis Migration↓, invasion↓, EMT↓, YAP1/VEGFA↓, p65↓ Repair migration↑ in wound contexts (context-dependent) G Reduced metastatic phenotype in selected models Important because Centella can promote normal wound repair while suppressing tumor-cell invasion in some systems; interpretation is tissue-context dependent.
5 PI3K Akt mTOR STAT3 survival axis PI3K/Akt↓, mTOR↓, STAT3↓ (mainly asiatic acid) Mixed cytoprotection or survival signaling↔ R,G Reduced survival, proliferation, and metastatic signaling Better supported for asiatic acid than asiaticoside; include as related triterpene-family mechanism rather than asiaticoside-only claim.
6 Autophagy axis LC3-II↑, autophagy↑ (model-dependent) Autophagy↔ or ↑ (context-dependent) G Stress adaptation or autophagic cell death Direction and therapeutic meaning are model-dependent; can be pro-death or protective depending on tumor context.
7 ROS antioxidant NRF2 stress axis ROS↔ or ↑ during apoptosis (context-dependent) Oxidative stress↓, antioxidant defense↑, NRF2↔ or ↑ R,G Normal-cell protection and redox modulation Secondary mechanism.
8 TGF-β collagen fibroblast repair axis TGF-β effects↔ (context-dependent) Collagen synthesis↑, fibroblast activity↑, wound repair↑ G Tissue repair and matrix remodeling Core for Centella’s non-cancer use; potentially undesirable in some tumor-stroma or fibrosis contexts.
9 VEGF angiogenesis axis VEGFA↓ in some breast cancer models Angiogenesis↑ during wound repair (context-dependent) G Opposite effects depending on cancer versus repair context Important interpretive caution: normal repair biology and cancer biology may diverge.
10 Radiosensitization migration constraint Radiation-induced migration↓, invasion↓ Radioprotection↔ unknown G Anti-invasive adjunct signal after irradiation Evidence is preclinical and more anti-migration than classic radiosensitization
11 Clinical Translation Constraint High in-vitro exposure required (often) Rare hepatotoxicity risk; product variability G Limits systemic anticancer translation Bioavailability, formulation, extract standardization, dose limitation, and weak oncology trial evidence are the main constraints.

P: 0–30 min R: 30 min–3 hr G: >3 hr




AD relevance: Possible / preclinical. Interest is mainly through neuroinflammation, oxidative stress, mitochondrial protection, and general neuroprotective mechanisms.

Alzheimer’s disease relevance: Centella asiatica / Gotu kola has a plausible but unproven AD-oriented profile. The strongest rationale is not direct amyloid clearance as an established clinical effect, but combined modulation of neuroinflammation, oxidative stress, mitochondrial metabolism, synaptic or neuronal viability markers, and vascular/microcirculatory support. Human evidence is early: phase-1 PK/safety and target-engagement studies exist in older adults with mild cognitive impairment or mild Alzheimer’s disease, but efficacy remains unproven.

Clinical evidence status: AD / cognition evidence is preclinical plus small human and phase-1 clinical work. Early translational / investigational rather than established therapy.

Cancer relevance: Weak / preclinical.

AD-Oriented Mechanistic Profile

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Neuroinflammation NF-κB cytokine axis NF-κB↓, TNF-α↓, IL-1β↓ Reduced inflammatory signaling Most defensible AD-relevant mechanism; not disease-specific.
2 Mitochondrial metabolism neuronal viability Mitochondrial function↑, metabolic stress↓ Neuronal bioenergetic support Central to current target-engagement rationale in cognitive impairment studies.
3 Oxidative stress DNA oxidation axis Oxidative stress↓, 8OHdG↓ (candidate marker) Reduced oxidative injury Relevant to trial biomarker strategy; clinical disease modification unproven.
4 Synaptic memory and neuronal morphology axis Learning and memory markers↑ (model-dependent) Cognitive-support signal in animals Preclinical support is stronger than human efficacy evidence.
5 Amyloid-associated pathology β-amyloid stress↓ (model-dependent) Reduced amyloid-model metabolic disturbance model-dependent, not as proven anti-amyloid clinical activity.
6 Clinical Translation Constraint Bioavailability↔, extract variability↑, evidence limitation↑ Limits AD clinical interpretation Current status is investigational; formulation, heavy-metal quality, dose, and trial endpoints matter.


LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
6660- Cen,    Hepatoprotective effect of Centella asiatica 50% ethanol extract against acetaminophen-induced acute liver injury in BALB/c mice
*hepatoP↑, *NO↓, *lipid-P↓, *IL1β↓, *ALAT↓, *AST↓, *LDH↓, GSH↑, MDA↓,
6656- Cen,    Recent insights into therapeutic potential and nanostructured carrier systems of Centella asiatica: An evidence-based review
- Review, Var, NA - Review, AD, NA
AntiCan↑, *AntiDiabetic↑, *neuroP↑, *antiOx↑, *cardioP↑, *Inflam↓, *hepatoP↑, *AntiAge↑, *AST↓, *ALAT↓, *LDH↓, *lipid-P↓, Casp3↑, *memory↑, *Wound Healing↑, eff↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   MDA↓, 1,  

Cell Death ⓘ

Casp3↑, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   lipid-P↓, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 2,   LDH↓, 2,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   Inflam↓, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   AST↓, 2,   LDH↓, 2,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   hepatoP↑, 2,   memory↑, 1,   neuroP↑, 1,   Wound Healing↑, 1,  
Total Targets: 17

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:417  Target#:906  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page